Open AccessImatinib mesylate induces responses in patients with liver metastases from gastrointestinal stromal tumor failing intra-arterial hepatic chemotherapy
Author(s) -
Giammaria Fiorentini,
Paolo Bernardeschi,
S. Rossi,
Patrizia Dentico,
Mauro Biancalani,
G. Giustarini,
Gina Turrisi
Publication year - 2006
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.25853
Subject(s) - imatinib mesylate , medicine , gist , chemotherapy , thalidomide , imatinib , stromal tumor , mesylate , gastroenterology , oncology , stromal cell , multiple myeloma , chemistry , myeloid leukemia , organic chemistry
Imatinib mesylate represents a real major paradigm shift in cancer therapy, targeting the specific molecular abnormalities, crucial in the etiology of tumor. Intra-arterial hepatic chemotherapy (IAHC) followed by embolization, has been considered an interesting palliative option for patients with liver metastases from gastrointestinal stromal tumor (GIST), due to the typically hypervascular pattern of the tumor.